SCHEMBL12828186

SCHEMBL12828186

CS(=O)(=O)c1ccc2c(c1)C(OCO)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 5/20 0.43
CYP3A4 P08684 2/20 0.40
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
KDM1A O60341 1/20 0.39
HTR6 P50406 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
DRD3 P35462 1/20 0.36
TMEM97 Q5BJF2 4/20 0.36
KCNH2 Q12809 3/20 0.36
SIGMAR1 Q99720 3/20 0.36
PTGS2 P35354 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1003328 0.77 CYP3A4 (0.46) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL27827582 0.74 KDM1A (0.50) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL13073826 0.74 CYP3A4 (0.42) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL13698772 0.74 CYP3A4 (0.42) PNMTCYP3A4IDO1TDO2KDM1A
Hydrochloric Acid SCHEMBL1005342 0.73 KDM1A (0.49) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL14388811 0.72 KDM1A (0.43) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL29649410 0.72 HTR6 (0.46) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL13698768 0.71 KDM1A (0.42) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL17729388 0.69 HTR6 (0.49) PNMTCYP3A4IDO1TDO2KDM1A
SCHEMBL1020247 0.68 PNMT (0.48) PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915253-B2 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury KALYPSYS, INC (US) 2011-03-29 US disclosed
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD PNMT 2166/4885CYP3A4 1506/4885IDO1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.